[1] |
上海市微生物学会临床微生物学专业委员会, 上海市医学会检验医学专科分会, 上海市医学会危重病专科分会. 血流感染临床检验路径专家共识[J]. 中华传染病杂志, 2022, 40(8):457-475.
|
[2] |
SULEYMAN G, ALANGADEN G J. Nosocomial fungal infections:epidemiology,infection control,and prevention[J]. Infect Dis Clin North Am, 2021, 35(4):1027-1053.
|
[3] |
ALVES J, PALMA P, AZEVEDO D, et al. Candidemia in the patient with malignancy[J]. Hosp Pract(1995),2018, 46(5):246-252.
|
[4] |
ANTINORI S, MILAZZO L, SOLLIMA S, et al. Candidemia and invasive candidiasis in adults:a narrative review[J]. Eur J Intern Med, 2016,34:21-28.
|
[5] |
MCCARTY T P, WHITE C M, PAPPAS P G. Candidemia and invasive candidiasis[J]. Infect Dis Clin North Am, 2021, 35(2):389-413.
|
[6] |
中华人民共和国卫生部. 医院感染诊断标准(试行)[J]. 中华医学杂志, 2001, 81(5):314-320.
|
[7] |
尚红, 王毓三, 申子瑜. 全国临床检验操作规程[M]. 4版. 北京: 人民卫生出版社, 2015.
|
[8] |
Clinical and Laboratory Standards Institute. Performance standards for antifungal susceptibility testing of yeasts[S]. M27 M44S,CLSI, 2022.
|
[9] |
Clinical and Laboratory Standards Institute. Epidemiological cutoff values for antifungal susceptibility testing[S]. M57s,CLSI, 2022.
|
[10] |
GHEORGHE D C, NICULESCU A G, BÎRCĂ A C, et al. Biomaterials for the prevention of oral candidiasis development[J]. Pharmaceutics, 2021, 13(6):803.
|
[11] |
KOEHLER P, STECHER M, CORNELY O A, et al. Morbidity and mortality of candidaemia in Europe:an epidemiologic meta-analysis[J]. Clin Microbiol Infect, 2019, 25(10):1200-1212.
|
[12] |
KEIGHLEY C, CHEN S C, MARRIOTT D, et al. Candidaemia and a risk predictive model for overall mortality:a prospective multicentre study[J]. BMC Infect Dis, 2019, 19(1):445.
|
[13] |
PAIVA J A, PEREIRA J M, TABAH A, et al. Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs:data from the EUROBACT study[J]. Crit Care, 2016,20:53.
|
[14] |
TABAH A, KOULENTI D, LAUPLAND K, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units:the EUROBACT international cohort study[J]. Intensive Care Med, 2012, 38(12):1930-1945.
|
[15] |
NGUYEN M H, OSTROSKY-ZEICHNER L, PAPPAS P G, et al. Real-world use of mold-active triazole prophylaxis in the prevention of invasive fungal diseases:results from a subgroup analysis of a multicenter national registry[J]. Open Forum Infect Dis, 2023, 10(9):ofad424.
|
[16] |
OSTROSKY-ZEICHNER L, NGUYEN M H, BUBALO J, et al. Multicenter registry of patients receiving systemic mold-active triazoles for the management of invasive fungal infections[J]. Infect Dis Ther, 2022, 11(4):1609-1629.
|
[17] |
DENNING D W. Global incidence and mortality of severe fungal disease[J]. Lancet Infect Dis, 2024, 24(7):e428-e438.
|
[18] |
TAEI M, CHADEGANIPOUR M, MOHAMMADI R. An alarming rise of non-albicans Candida species and uncommon yeasts in the clinical samples;a combination of various molecular techniques for identification of etiologic agents[J]. BMC Res Notes, 2019, 12(1):779.
|
[19] |
GÓMEZ-GAVIRIA M, RAMÍREZ-SOTELO U, MORA-MONTES H M. Non-albicans Candida species:immune response,evasion mechanisms,and new plant-derived alternative therapies[J]. J Fungi(Basel), 2022, 9(1):11.
|
[20] |
朱德妹, 吴文娟, 胡付品. 细菌真菌耐药监测实用手册[M]. 上海: 上海科学技术出版社, 2020.
|
[21] |
中华医学会重症医学分会. 重症患者侵袭性真菌感染诊断与治疗指南(2007)[J]. 中华内科杂志, 2007, 46(11):960-966.
|
[22] |
GUPTA S, SAKHUJA A, KUMAR G, et al. Culture-negative severe sepsis:nationwide trends and outcomes[J]. Chest, 2016, 150(6):1251-1259.
|
[23] |
FINKELMAN M A. Specificity influences in(1→3)-β-D-glucan-supported diagnosis of invasive fungal disease[J]. J Fungi(Basel), 2020, 7(1):14.
|
[24] |
MIKULSKA M, BALLETTO E, CASTAGNOLA E, et al. β-D-glucan in patients with haematological malignancies[J]. J Fungi(Basel), 2021, 7(12):1046.
|
[25] |
DEMIR ONDER K, SEREMET KESKIN A. Should preventive antifungal treatment be given to patients with abdominal contamination in the intensive care unit?[J]. Cureus, 2023, 15(2):e35071.
|
[26] |
IBA T, HELMS J, CONNORS J M, et al. The pathophysiology,diagnosis,and management of sepsis-associated disseminated intravascular coagulation[J]. J Intensive Care, 2023, 11(1):24.
|
[27] |
ANGUS D C, YEALY D M, KELLUM J A. Protocol-based care for early septic shock[J]. N Engl J Med, 2014, 371(4):386.
|
[28] |
LI D, XIA R, ZHANG Q, et al. Evaluation of candidemia in epidemiology and risk factors among cancer patients in a cancer center of China:an 8-year case-control study[J]. BMC Infect Dis, 2017, 17(1):536.
|